CO6290702A2 - Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos - Google Patents

Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos

Info

Publication number
CO6290702A2
CO6290702A2 CO10102866A CO10102866A CO6290702A2 CO 6290702 A2 CO6290702 A2 CO 6290702A2 CO 10102866 A CO10102866 A CO 10102866A CO 10102866 A CO10102866 A CO 10102866A CO 6290702 A2 CO6290702 A2 CO 6290702A2
Authority
CO
Colombia
Prior art keywords
replicate
alfavirus
recombinants
mosquitoes
attacked
Prior art date
Application number
CO10102866A
Other languages
English (en)
Spanish (es)
Inventor
Scott C Weaver
Iiya Frolov
Elena Frolova
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of CO6290702A2 publication Critical patent/CO6290702A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CO10102866A 2008-01-24 2010-08-20 Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos CO6290702A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6222908P 2008-01-24 2008-01-24

Publications (1)

Publication Number Publication Date
CO6290702A2 true CO6290702A2 (es) 2011-06-20

Family

ID=41217313

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10102866A CO6290702A2 (es) 2008-01-24 2010-08-20 Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos

Country Status (15)

Country Link
US (3) US8426188B2 (https=)
EP (2) EP2250269B1 (https=)
JP (1) JP5758632B2 (https=)
KR (2) KR101668849B1 (https=)
CN (1) CN102083986B (https=)
AU (1) AU2009238667A1 (https=)
CA (2) CA2910235C (https=)
CO (1) CO6290702A2 (https=)
IL (2) IL207167A (https=)
MX (3) MX367792B (https=)
MY (1) MY178870A (https=)
NZ (2) NZ603790A (https=)
SG (2) SG187513A1 (https=)
WO (1) WO2009131604A2 (https=)
ZA (1) ZA201005943B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2947149T3 (en) * 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
SG187513A1 (en) 2008-01-24 2013-02-28 Univ Texas Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
EP2900685B1 (en) 2012-09-27 2017-10-25 Research Development Foundation Attenuated chikungunya virus
JP6426695B2 (ja) 2013-03-14 2018-11-21 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 弱毒生アルファウイルス製剤のための組成物および方法
US20190106682A1 (en) * 2016-03-31 2019-04-11 Takeda Vaccines, Inc. Live, Attenuated Alphavirus Constructs and Methods and Uses Thereof
CN109476708B (zh) * 2016-05-27 2023-12-22 格里菲斯大学 针对致关节炎甲病毒的疫苗
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
SG11202005792RA (en) 2017-12-20 2020-07-29 Vlp Therapeutics Llc Alphavirus replicon particle
CA3111440A1 (en) * 2018-08-03 2020-02-06 Uab Research Foundation Methods and compositions for alphavirus vaccine
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
WO2021138447A1 (en) 2019-12-31 2021-07-08 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
KR20230046313A (ko) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
CA2327189A1 (en) * 2000-12-21 2002-06-21 The Minister Of National Defence Novel dna-based vaccine against the encephalitis alphaviruses
CN1791678A (zh) * 2003-03-20 2006-06-21 阿尔法瓦克斯公司 改进的甲病毒复制子和辅助构建体
CA2533614C (en) 2004-07-30 2011-05-03 Research In Motion Limited Method and system for coordinating device setting between a communications client and its host device
US7332322B2 (en) 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
CA2579507C (en) 2006-03-15 2017-06-13 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
SG187513A1 (en) * 2008-01-24 2013-02-28 Univ Texas Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Also Published As

Publication number Publication date
EP2250269A2 (en) 2010-11-17
EP2250269A4 (en) 2012-01-04
AU2009238667A1 (en) 2009-10-29
MX378503B (es) 2025-03-11
JP5758632B2 (ja) 2015-08-05
JP2011523347A (ja) 2011-08-11
CA2910235C (en) 2021-07-06
US20110052634A1 (en) 2011-03-03
CN102083986B (zh) 2014-06-18
KR101668849B1 (ko) 2016-10-24
MY178870A (en) 2020-10-21
SG10201606111XA (en) 2016-09-29
KR20100106599A (ko) 2010-10-01
US20170240919A1 (en) 2017-08-24
US8426188B2 (en) 2013-04-23
EP3085787A1 (en) 2016-10-26
EP2250269B1 (en) 2016-03-16
CA2713165C (en) 2015-12-29
IL232032A0 (en) 2014-05-28
NZ603790A (en) 2014-08-29
US10533186B2 (en) 2020-01-14
US20140010841A1 (en) 2014-01-09
KR20160124255A (ko) 2016-10-26
ZA201005943B (en) 2011-04-28
KR101913790B1 (ko) 2018-12-28
CN102083986A (zh) 2011-06-01
MX367792B (es) 2019-09-05
EP3085787B1 (en) 2020-10-28
CA2910235A1 (en) 2009-10-29
US9580690B2 (en) 2017-02-28
IL207167A0 (en) 2010-12-30
NZ587502A (en) 2012-12-21
CA2713165A1 (en) 2009-10-29
IL207167A (en) 2014-04-30
WO2009131604A2 (en) 2009-10-29
SG187513A1 (en) 2013-02-28
MX2019010530A (es) 2019-10-15
MX2010007989A (es) 2010-12-21
WO2009131604A3 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
CO6290702A2 (es) Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos
ECSP23013715A (es) Composiciones y métodos de construcciones quiméricas del virus del dengue en vacunas
PA8815301A1 (es) Ido5 antagonistas de pcsk9
UY37563A (es) Aislados de bacillus y usos de los mismos
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
MX2024008058A (es) Adenovirus modificados.
ECSP18081582A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
BR112015011244A2 (pt) Análogos de compstatina de ação prolongada, método de fabricação e uso dos mesmos, bem como composição de qualidade farmacêutica
CO6761348A2 (es) Compuestos antivirales
CO6420394A2 (es) Estructura tipo lamina insecticida para proteger seres humanos y animales domesticos
ECSP12011637A (es) Polipéptidos del factor ix modificados y usos de los mismos
CL2013000505A1 (es) Estructura fibrosa fijada y/o estabilizada de un material fibroso asi como un agente para su fijacion y estabilizacion, donde dicho agente es al menos un copoliester estadistico formado por: acido tereftalico, acido isoftalico, butanodiol, dietilenglicol, trietilenglicol; metodo de fabricacion; material compuesto de resina-fibra; y uso de dicha estructura.
WO2014026151A8 (en) Compositions, apparatus, systems, and methods for resolving electronic excited states
MX2020005235A (es) Celula humana transformada y uso de la misma.
AR090606A1 (es) Composicion pesticida
MX2018006373A (es) Produccion de virus en cultivos celulares.
CR20140040A (es) Compuestos de antranilamida y sus usos como plaguicidas
WO2012065105A3 (en) Chimeric flavivirus vaccines
CR20140041A (es) Compuestos de antranilamida y sus usos como plaguicidas
BR112015011254A2 (pt) Utilização de um composto constituído por uma unidade de polifluorobenzilo contra pragas resistentes a inseticidas
BR112015013071A8 (pt) solução de trombina aquosa, seus métodos para liofilização e composição de trombina sólida
AR083215A1 (es) Combinacion sinergica de abamectina y bifentrina, su proceso de preparacion y uso, y metodo utilizando la misma
WO2014060851A3 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
BR112013013960A8 (pt) Composi%c3%87%c3%95es de vacinas de mal%c3%81ria, polipept%c3%8ddeos, fragmentos do mesmo, mol%c3%89culas de %c3%81cido nucleico, e usos destes
ATE456303T1 (de) Verwendung von cni-sl-formulierungen zur bekämpfung der weissen fliege

Legal Events

Date Code Title Description
FG Application granted